270 related articles for article (PubMed ID: 29956186)
1. Utilization of Feline ELISpot to Evaluate the Immunogenicity of a T Cell-Based FIV MAP Vaccine.
Sahay B; Aranyos AM; McAvoy A; Yamamoto JK
Methods Mol Biol; 2018; 1808():197-219. PubMed ID: 29956186
[TBL] [Abstract][Full Text] [Related]
2. An initial examination of the potential role of T-cell immunity in protection against feline immunodeficiency virus (FIV) infection.
Aranyos AM; Roff SR; Pu R; Owen JL; Coleman JK; Yamamoto JK
Vaccine; 2016 Mar; 34(12):1480-8. PubMed ID: 26802606
[TBL] [Abstract][Full Text] [Related]
3. Immunogenicity and Efficacy of a Novel Multi-Antigenic Peptide Vaccine Based on Cross-Reactivity between Feline and Human Immunodeficiency Viruses.
Sahay B; Aranyos AM; Mishra M; McAvoy AC; Martin MM; Pu R; Shiomitsu S; Shiomitsu K; Dark MJ; Sanou MP; Roff SR; Rathore MH; Yamamoto JK
Viruses; 2019 Feb; 11(2):. PubMed ID: 30717485
[TBL] [Abstract][Full Text] [Related]
4. HIV-1 p24 vaccine protects cats against feline immunodeficiency virus infection.
Coleman JK; Pu R; Martin M; Sato E; Yamamoto JK
AIDS; 2005 Sep; 19(14):1457-66. PubMed ID: 16135898
[TBL] [Abstract][Full Text] [Related]
5. Peptide mapping of feline immunodeficiency virus by IFN-gamma ELISPOT.
Dean GA; LaVoy A; Burkhard MJ
Vet Immunol Immunopathol; 2004 Jul; 100(1-2):49-59. PubMed ID: 15182995
[TBL] [Abstract][Full Text] [Related]
6. Efficacy evaluation of prime-boost protocol: canarypoxvirus-based feline immunodeficiency virus (FIV) vaccine and inactivated FIV-infected cell vaccine against heterologous FIV challenge in cats.
Tellier MC; Pu R; Pollock D; Vitsky A; Tartaglia J; Paoletti E; Yamamoto JK
AIDS; 1998 Jan; 12(1):11-8. PubMed ID: 9456250
[TBL] [Abstract][Full Text] [Related]
7. Dual-subtype FIV vaccine protects cats against in vivo swarms of both homologous and heterologous subtype FIV isolates.
Pu R; Coleman J; Omori M; Arai M; Hohdatsu T; Huang C; Tanabe T; Yamamoto JK
AIDS; 2001 Jul; 15(10):1225-37. PubMed ID: 11426067
[TBL] [Abstract][Full Text] [Related]
8. Lessons Learned in Developing a Commercial FIV Vaccine: The Immunity Required for an Effective HIV-1 Vaccine.
Sahay B; Yamamoto JK
Viruses; 2018 May; 10(5):. PubMed ID: 29789450
[TBL] [Abstract][Full Text] [Related]
9. Cellular immune responses to feline immunodeficiency virus (FIV) induced by dual-subtype FIV vaccine.
Omori M; Pu R; Tanabe T; Hou W; Coleman JK; Arai M; Yamamoto JK
Vaccine; 2004 Dec; 23(3):386-98. PubMed ID: 15530685
[TBL] [Abstract][Full Text] [Related]
10. Immunization of cats against feline immunodeficiency virus (FIV) infection by using minimalistic immunogenic defined gene expression vector vaccines expressing FIV gp140 alone or with feline interleukin-12 (IL-12), IL-16, or a CpG motif.
Leutenegger CM; Boretti FS; Mislin CN; Flynn JN; Schroff M; Habel A; Junghans C; Koenig-Merediz SA; Sigrist B; Aubert A; Pedersen NC; Wittig B; Lutz H
J Virol; 2000 Nov; 74(22):10447-57. PubMed ID: 11044089
[TBL] [Abstract][Full Text] [Related]
11. Utilization of feline ELISPOT for mapping vaccine epitopes.
Abbott JR; Pu R; Coleman JK; Yamamoto JK
Methods Mol Biol; 2012; 792():47-63. PubMed ID: 21956500
[TBL] [Abstract][Full Text] [Related]
12. Involvement of gag- and env-specific cytotoxic T lymphocytes in protective immunity to feline immunodeficiency virus.
Flynn JN; Beatty JA; Cannon CA; Stephens EB; Hosie MJ; Neil JC; Jarrett O
AIDS Res Hum Retroviruses; 1995 Sep; 11(9):1107-13. PubMed ID: 8554908
[TBL] [Abstract][Full Text] [Related]
13. Conserved epitopes on HIV-1, FIV and SIV p24 proteins are recognized by HIV-1 infected subjects.
Roff SR; Sanou MP; Rathore MH; Levy JA; Yamamoto JK
Hum Vaccin Immunother; 2015; 11(6):1540-56. PubMed ID: 25844718
[TBL] [Abstract][Full Text] [Related]
14. Vaccination of cats with attenuated feline immunodeficiency virus proviral DNA vaccine expressing gamma interferon.
Gupta S; Leutenegger CM; Dean GA; Steckbeck JD; Cole KS; Sparger EE
J Virol; 2007 Jan; 81(2):465-73. PubMed ID: 17079309
[TBL] [Abstract][Full Text] [Related]
15. Immunization-induced decrease of the CD4+:CD8+ ratio in cats experimentally infected with feline immunodeficiency virus.
Lehmann R; von Beust B; Niederer E; Condrau MA; Fierz W; Aubert A; Ackley CD; Cooper MD; Tompkins MB; Lutz H
Vet Immunol Immunopathol; 1992 Dec; 35(1-2):199-214. PubMed ID: 1363009
[TBL] [Abstract][Full Text] [Related]
16. Recombinant FeLV vaccine: long-term protection and effect on course and outcome of FIV infection.
Hofmann-Lehmann R; Holznagel E; Aubert A; Ossent P; Reinacher M; Lutz H
Vet Immunol Immunopathol; 1995 May; 46(1-2):127-37. PubMed ID: 7618252
[TBL] [Abstract][Full Text] [Related]
17. Protection against FIV challenge infection by genetic vaccination using minimalistic DNA constructs for FIV env gene and feline IL-12 expression.
Boretti FS; Leutenegger CM; Mislin C; Hofmann-Lehmann R; König S; Schroff M; Junghans C; Fehr D; Huettner SW; Habel A; Flynn JN; Aubert A; Pedersen NC; Wittig B; Lutz H
AIDS; 2000 Aug; 14(12):1749-57. PubMed ID: 10985311
[TBL] [Abstract][Full Text] [Related]
18. FIV vaccine studies. I. Immune response to recombinant FIV env gene products and outcome after challenge infection.
Lutz H; Hofmann-Lehmann R; Bauer-Pham K; Holznagel E; Tozzini F; Bendinelli M; Reubel G; Aubert A; Davis D; Cox D
Vet Immunol Immunopathol; 1995 May; 46(1-2):103-13. PubMed ID: 7618250
[TBL] [Abstract][Full Text] [Related]
19. MHC-restricted protection of cats against FIV infection by adoptive transfer of immune cells from FIV-vaccinated donors.
Pu R; Omori M; Okada S; Rine SL; Lewis BA; Lipton E; Yamamoto JK
Cell Immunol; 1999 Nov; 198(1):30-43. PubMed ID: 10612649
[TBL] [Abstract][Full Text] [Related]
20. Dual-subtype FIV vaccine (Fel-O-Vax FIV) protection against a heterologous subtype B FIV isolate.
Pu R; Coleman J; Coisman J; Sato E; Tanabe T; Arai M; Yamamoto JK
J Feline Med Surg; 2005 Feb; 7(1):65-70. PubMed ID: 15686976
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
